GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY OUTLOOK 2014: RISING STARS

Global Pharmaceutical & Biotechnology Outlook 2014: Rising Stars

Innovations have contributed to the availability of a range of new treatments for diseases resulting in improvement in the length and quality of life and reduced disease burden for individuals and society. However, the need for innovative therapies for unmet needs /challenging diseases continues to grow, accelerating the pace of drug development directly or through partnership/ in-licensing. We expect innovation and improved drugs therapies through novel target discovery and technology platforms to continue to flow from the backyards of small research focused companies (Rising Stars, RS – non-profitable biotech companies) in coming years.

Approval of new drugs, successful launches, maturing pipeline sustained the growth trajectory of biotech companies resulting in successful IPOs. We expect the optimism to percolate further into companies with novel technology platforms and targets. For more details on the trend in drug approvals, upcoming milestones and M&A in coming years please see Global Pharmaceutical and Biotechnology Outlook 2014 :Rising Stars

Read » Global Pharmaceutical & Biotechnology Outlook 2014: Rising Stars

Published 1 year 7 weeks ago
Category: Health | Tags:

Login or register to post comments

Stories similar to Global Pharmaceutical & Biotechnology Outlook 2014: Rising Stars:

Additional information on Global Pharmaceutical & Biotechnology Outlook 2014: Rising Stars :
- Feb 10, 2014 ... Insightful research report “Global Pharmaceutical and Biotechnology Outlook 2014 :Rising Stars” worked out by MP Advisors has been recently ...
- Research and Markets: Global Pharmaceutical and Biotechnology Outlook 2014: Rising Stars. – March 27, 2014 Posted in: BioPharma News, Pharma Finance.
- 6 hours ago ... Global Pharmaceutical & Biotechnology Outlook 2014: Rising Stars. Bharat Book Bureau presents the new report, on "Global Pharmaceutical ...
- 4 days ago ... DUBLIN---- Research and Markets has announced the addition of the "Global Pharmaceutical and Biotechnology Outlook 2014: Rising Stars" ...
- Feb 5, 2014 ... Innovations have contributed to the availability of a range of new treatments for diseases resulting in improvement in the length and quality of ...
- 3 days ago ... DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Global Pharmaceutical and Biotechnology Outlook 2014: Rising Stars.
- Global Pharmaceutical and Biotechnology Outlook 2014: Rising Stars - PR ... Global Pharmaceutical & Biotechnology Outlook 2014: Major US and EU - PR ...
- Mar 14, 2014 ... Reportstack has announced a new market research publication on Global Pharmaceutical and Biotechnology Outlook 2014 :Rising Stars.

Related links about Global Pharmaceutical & Biotechnology Outlook 2014: Rising Stars :
1. Global Pharmaceutical & Biotechnology Outlook 2014: Rising Stars ...
2. Research and Markets: Global Pharmaceutical and Biotechnology ...
3. Global Pharmaceutical and Biotechnology Outlook 2014: Rising Stars
4. Global Pharmaceutical and Biotechnology Outlook 2014 :Rising Stars
5. World Pharma and Biotech Market Examined by MP Advisors in Its ...

Global Pharmaceutical & Biotechnology Outlook 2013: Rising Stars 1 year 24 weeks ago: Global Biopharmaceutical Outlook 2013 of the Rising Stars sector provides an in depth analyses of biotech companies and their drug pipeline amidst competition and dynamic regulatory environment. The report discusses the competitive landscape of the targeted therapy areas and the innovative strategy each company is deploying to surmount challenges and remain attractive for acquisitions, partnerships or march toward profitability. Sum of parts valuations of drugs in the pipeline are included after factoring clinical development risks and competition.
Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech 1 year 7 weeks ago: Positive sentiments for the biotech sector have prevailed in the last two to three years, and we expect this trend to continue for the next year too. Our optimism is based on the continuity in the flow of innovative products from their pipeline, implementation of strategic decisions to improve cost efficiency, strengthen therapeutic leadership, and hedge against generic threats – which all lend stability to the business model of the company. Focus and interest in Orphan diseases remains and Alexion kept everyone guessing on the possible acquisition.
Global Pharmaceutical & Biotechnology Outlook 2 years 18 weeks ago: Bharat Book Bureau has announced the addition of the "Global Pharmaceutical & Biotechnology Outlook 2013: Global Pharma" report to their offering.
PharmaLeaders: Mid-Cap Biotechnology Benchmark Report 6 weeks 2 days ago: Summary
Global Orphan Cancer Drug Market & Clinical Pipeline Insight 14 weeks 2 days ago: The drug development strategies of the pharmaceutical companies is undergoing a paradigm shift from manufacturing traditional essential medicines to orphan drugs due to significant competition from generics and the associated economic situation. The returns on investment from orphan drugs are expected to help the pharma companies to overcome the impact of revenue loss due to expiry of patents of blockbuster drugs.